AxoGen (NASDAQ: AXGN) reported Q4 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $42.9 million versus the consensus estimate of $41.25 million.

GUIDANCE:

AxoGen sees FY2024 revenue of $177-181 million, versus the consensus of $179.2 million, which represents an annual growth rate of approximately 11% to 14%. Additionally, we anticipate gross margin for the full year to be in the range of 76% to 79%.

For earnings history and earnings-related data on AxoGen (AXGN) click here.